AAAylin Akifova

Aylin Akifova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aylin Akifova has a total of 103 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • NK cell missing self in microvascular inflammation with and without donor-specific antibodies

    by Benedetta Mordà, Aylin Akifova, Matthias Diebold, Nils Lachmann, Mareen Pigorsch, Hannes Vietzen, Elisabeth Puchhammer-Stöckl, Laura M Kühner, Sarah M Berger, Antje Lassahn, et al.

    Background and hypothesis: Microvascular inflammation (MVI), a histological hallmark of antibody-mediated rejection, is typically associated with donor-specific antibodies (DSA), but can also occur in their absence. Evidence implicates natural killer (NK) cells in DSA-negative MVI, although the mechanisms underlying their activation remain unclear. Methods: We retrospectively analyzed 165 kidney transplant biopsies, regarding biopsy-based diagnostic categories as competing events: (1) MVI + DSA+ (n = 91), (2) MVI + DSA- (n = 35), and (3) MVI - DSA+ (n = 39). Recipients and donors were genotyped for killer-cell immunoglobulin-like receptor (KIR) and Human Leukocyte Antigen (HLA) to assess “missing self”-the absence of donor HLA ligands for recipient inhibitory KIR. We also tested the moderating effect of NK cell functional polymorphisms in FCGR3A (V/F158), KLRK1 (LNK/HNK), KLRC2 (wt/del), and rs9916629. We used cumulative incidence functions and cause-specific Cox regression models to examine the association of genetic variants and the incidence of the competing biopsy-based diagnostic categories. Results: The presence of missing self was associated with a lower hazard of MVI - DSA+ occurrence (hazard ratio [HR] 0.37, 95% confidence interval [CI]: 0.16–0.84, P = 0.017); (adjusted HR 0.42, 95% CI: 0.18-1.00, P = 0.051), while a trend suggested a higher incidence of MVI + DSA- diagnosis when missing self was present (HR: 1.43, 95% CI: 0.71–2.89, P = 0.313; adjusted HR 1.53, 95% CI: 0.72–3.25, P = 0.269). None of NK high functional polymorphisms had a moderating effect on the relation between missing self and biopsy-based diagnostic categories. Conclusion: These findings suggest that missing self is unlikely to increase the probability of MVI per se. On the other hand, missing self decreases the likelihood of biopsy findings being free of MVI in patients who develop DSA. Given the selected, biopsy-based cohort and the absence of an MVI - DSA- comparison group, these findings are exploratory and require validation in larger, prospectively defined cohorts.

  • Open Access

    A multicenter registry study of the CD38 antibody daratumumab for the treatment of microvascular inflammation following kidney transplantation

    by Thomas Drasch, Katharina A. Mayer, Georg A. Böhmig, Aylin Akifova, Fabian Halleck, Klemens Budde, David Rohlfing, Christian Hinze, Malte Kluger, Florian Grahammer, et al.


  • Open Access

    Prolonged CD38 targeting with felzartamab in antibody-mediated kidney transplant rejection: a biomarker-guided open-label phase 2 extension

    by Katharina A. Mayer, Matthias Diebold, Eva V. Schrezenmeier, Philip F. Halloran, Susanne Haindl, Martina Schatzl, Aylin Akifova, Daniela M. Allmer, Sabine Schranz, Nicolas Kozakowski, et al.


  • Open Access

    Improving diagnostic performance of kidney allograft rejection with a model combining relative fraction and absolute copies of donor-derived cell-free DNA—Results from 5 independent cohorts

    by Louise Benning, Aylin Akifova, Michael Oellerich, Bilgin Osmanodja, Christian Morath, Julia Beck, Ana Schuetz, Kirsten Bornemann-Kolatzki, Eva V. Schrezenmeier, Thuong Hien Tran, et al.


  • Open Access

    Believing in the Nobel Prize: Long-term Success After HLA-Identical Kidney Transplantation in 3 Monozygotic Twins Without any Induction or Maintenance Immunosuppression

    by Aylin Akifova, Ömer Ege Ömeroğlu, Fabian Halleck, Bilgin Osmanodja, Eva Vanessa Schrezenmeier, Friederike Bachmann, Diana Stauch, Nils Lachmann, Klemens Budde

    Background.: Kidney transplantation between HLA-identical monozygotic twins offers a unique chance for long-term graft survival without immunosuppression. Although favorable outcomes after withdrawal of maintenance immunosuppression have been reported, complete omission remains uncommon, and immunosuppressive strategies are not standardized across centers. Methods.: We report 3 HLA-identical monozygotic twin pairs who underwent kidney transplantation without induction or maintenance immunosuppression. Allograft function was monitored longitudinally, with follow-up durations of 22, 10, and 4 y, respectively. All patients had immediate and sustained excellent graft function with no rejection episodes or native disease recurrence during follow-up. Results.: Patient 1 was a 29-y-old man with chronic glomerulonephritis and had a largely uneventful course posttransplant. Patient 2 was a 61-y-old man who received his third graft from his monozygotic twin. Although highly sensitized because of previous transplants (calculated panel-reactive antibody = 62%), no desensitization or immunosuppressive therapy was administered, and graft function remained excellent without rejection. Patient 3 was a 43-y-old woman with IgA nephropathy, who was transplanted in high-risk cytomegalovirus constellation (donor [+]/recipient [–]). She developed a primary cytomegalovirus infection after cessation of 3-mo prophylaxis, which was successfully treated with valganciclovir. Conclusions.: This case series demonstrates that kidney transplantation between HLA-identical monozygotic twins can achieve excellent long-term graft survival without any induction or maintenance immunosuppression.


  • Open Access

    Association of Blood Donor-derived Cell-free DNA Levels With Banff Scores and Histopathological Lesions in Kidney Allograft Biopsies: Results From an Observational Study

    by Aylin Akifova, Klemens Budde, Mira Choi, Kerstin Amann, Maike Buettner-Herold, Michael Oellerich, Julia Beck, Kirsten Bornemann-Kolatzki, Ekkehard Schütz, Friederike Bachmann, et al.

    Background. Donor-derived cell-free DNA (dd-cfDNA) is an emerging biomarker of kidney allograft injury, mainly investigated in the context of rejection. However, the dd-cfDNA dynamics in other graft pathologies merit further investigation. Methods. In this single-center observational study, we prospectively collected dd-cfDNA at indication biopsies. To evaluate the association between dd-cfDNA and different histological patterns, we correlated absolute and relative dd-cfDNA (thresholds of 50 copies/mL and 0.5%, respectively) with the Banff 2022 lesion scores and the assigned diagnoses. Results. We examined 151 dd-cfDNA paired biopsies in 131 kidney transplant recipients and found significantly higher absolute dd-cfDNA levels in antibody-mediated rejection (n, median, IQR: 45, 63 copies/mL, 42–89), microvascular inflammation (MVI) without donor-specific antibodies or C4d-deposition (6, 102 copies/mL, 61–134), mixed rejection (8, 140 copies/mL, 77–171), and BK virus–associated nephropathy (6, 213 copies/mL, 83–298) compared with glomerulonephritis (20, 12 copies/mL, 8–18), calcineurin toxicity (19, 10 copies/mL, 7–16), interstitial fibrosis/tubular atrophy (12, 10 copies/mL, 9–16) and normal histology (6, 9 copies/mL, 7–16). In the multivariable analysis, absolute and relative dd-cfDNA correlated with the peritubular capillaritis (ptc), glomerulitis (g), and tubulitis (t) scores. In the receiver operating characteristic analysis, absolute dd-cfDNA showed best discrimination for MVI of any cause (area under the curve [AUC] 0.88, sensitivity 0.71, specificity 0.86, positive predictive value [PPV] 0.76, negative predictive value [NPV] 0.82), followed by antibody-mediated rejection including mixed rejection (AUC 0.85, sensitivity 0.72, specificity 0.83, PPV 0.69, NPV 0.84), and overall rejection (AUC 0.83, sensitivity 0.66, specificity 0.85, PPV 0.76, NPV 0.77). T cell–mediated rejection was only detectable by dd-cfDNA when associated with vascular lesions. Conclusions. Altogether, we conclude that dd-cfDNA-release is not limited to rejection-related injury phenotypes and is mainly driven by MVI in kidney allografts. Export


  • Open Access

    Estimating the efficacy of felzartamab to treat antibody-mediated rejection using the iBox prognostication system

    by Yannis Lombardi, Marc Raynaud, Martina Schatzl, Katharina A. Mayer, Matthias Diebold, Uptal D. Patel, Eva Schrezenmeier, Aylin Akifova, Klemens Budde, Alexandre Loupy, et al.


  • Open Access

    Donor-derived cell-free DNA monitoring for early diagnosis of antibody-mediated rejection after kidney transplantation: a randomized trial

    by Aylin Akifova, Klemens Budde, Kerstin Amann, Maike Buettner-Herold, Mira Choi, Michael Oellerich, Julia Beck, Kirsten Bornemann-Kolatzki, Ekkehard Schütz, Friederike Bachmann, et al.

    Background: Donor-derived cell-free DNA (dd-cfDNA) shows good diagnostic performance for the detection of antibody-mediated rejection (AMR) in kidney transplant recipients (KTR). However, the clinical benefits of dd-cfDNA monitoring need to be established. Early diagnosis of AMR at potentially reversible stages may be increasingly important due to emerging treatment options for AMR. We hypothesized that monitoring dd-cfDNA in KTR with de novo donor-specific anti-HLA antibodies (dnDSA) and performing kidney biopsy in case of increased dd-cfDNA may reduce time to AMR diagnosis in comparison with clinical indication biopsy. Methods: In this diagnostic, single-center, open-label, randomized clinical trial, we assigned 40 KTR with prevalent dnDSA and estimated glomerular filtration rate ≥20 mL/min/1.73 m2, but without previous biopsy-proven AMR, to either dd-cfDNA-guided biopsy (intervention group) or clinician-guided biopsy (control group) over a 12-month period. In both groups, dd-cfDNA was assessed at inclusion and 1, 3, 6, 9 and 12 months. In the intervention group, dd-cfDNA >50 copies/mL indicated a biopsy. Biopsies for clinical indication could be performed at any point during the study period in both groups. A protocol biopsy was scheduled after 12 months for patients without dd-cfDNA-guided biopsy or clinical indication biopsy until study completion. The primary endpoint was time from study inclusion to diagnosis of active or chronic active AMR. Results: Thirty-nine of 40 patients had functioning grafts at study completion. From these, 26 patients underwent biopsy, 13 in each group. AMR was diagnosed earlier in the intervention group than in the control group [median 2.8 months, interquartile range (IQR) 1.7–5.3 vs median 14.5 months, IQR 13.3–16.7, P = .003]. Longitudinal dd-cfDNA monitoring had 77% positive predictive value and 85% negative predictive value for AMR. Conclusions: Dd-cfDNA-guided biopsy in KTR with prevalent dnDSA can reduce the time to AMR diagnosis and hereby expedite therapy initiation. Trial registration: ClinicalTrials.gov, NCT04897438.


  • Open Access

    Perspective for Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection After Kidney Transplantation: Defining Context of Use and Clinical Implications

    by Aylin Akifova, Klemens Budde, Michael Oellerich, Julia Beck, Kirsten Bornemann-Kolatzki, Ekkehard Schütz, Bilgin Osmanodja

    Antibody-mediated rejection (AMR) is a major cause of graft failure limiting long-term graft survival after kidney transplantation. Current diagnostic strategy to detect AMR is suboptimal and requires further improvement. Previously suggested treatment regimens for AMR could not demonstrate efficacy, however novel therapeutic agents are currently under investigation. Donor-derived cell-free DNA (dd-cfDNA) is a novel non-invasive biomarker for allograft injury, that has been mainly studied in the context of rejection. Its short-half-life in circulation and injury-dependent release are its key advantages that contribute to its superior diagnostic accuracy, compared to traditional biomarkers. Moreover, previous studies showed that dd-cfDNA-release is well-linked to histological and molecular features of AMR, and thus able to reflect real-time injury. Further observations suggest that dd-cfDNA can be used as a suitable screening tool for early detection of AMR in patients with donor-specific-anti-HLA-antibodies (DSA), as well as for monitoring AMR activity after anti-rejection treatment. The weight of evidence suggests that the integration of dd-cfDNA in the graft surveillance of patients with AMR, or those suspicious of AMR (e.g., due to the presence of donor-specific anti-HLA-antibodies) has an added value and might have a positive impact on outcomes in this specific cohort.


  • Open Access

    Donor-Derived Cell-Free DNA in Biopsy-Proven Antibody-Mediated Rejection Versus Recurrent IgA Nephropathy After Kidney Transplantation

    by Aylin Akifova, Klemens Budde, Mira Choi, Michael Oellerich, Julia Beck, Kirsten Bornemann-Kolatzki, Ekkehard Schütz, Jan Kowald, Bilgin Osmanodja